(NVET) - Earnings & Price History

NVET: - 6.72, $0.00M, 0.00 (0.00%)

Sector: Healthcare - Industry: Biotechnology

Nexvet Biopharma public limited company, a clinical-stage biopharmaceutical company, focuses on developing and commercializing species-specific biologics. Its product candidates include Ranevetmab, a monoclonal antibody (mAb) that targets and inhibits the function of nerve growth factor (NGF) for the control of pain associated with osteoarthritis in dogs; and Frunevetmab, a mAb that targets NGF inhibitor for the control of pain associated with degenerative joint disease, including osteoarthritis in cats. The company is also developing NV-03, a mAb targeting NGF that is being evaluated as a therapy for chronic joint pain in horses. In addition, it has research and development collaboration with Zenoaq for applying PETization technology to convert mAb candidates into species-specific candidates in the areas of immuno-oncology, inflammation, and allergy. Nexvet Biopharma public limited comp

Past NVET reports
Earning DateTimeTitleEPS-e EPS-a ClosePrev CloseOpen Day LowDay High Gap % CFO %Change % Volume
2017-02-10-0.37
2016-11-04-0.41
2016-11-03-0.414.053.96833.963.894.13-0.21%▲2.27%2.06%13.65K
2016-09-02-0.48
2016-05-12-0.442.842.952.852.722.84-3.39%-0.35%-3.73%1.30K
2016-05-09-0.442.9982.922.972.8633.041.71%0.94%2.67%1.32K
2016-05-06-0.44
2016-02-16-0.472.913.183.22.93.380.63%-9.06%-8.49%16.39K
2015-11-05-0.55.625.265.195.195.83-1.33%▲8.29%6.84%53.38K

Login | Register
Saturday Nov 17, 2018   EST
Enter a Ticker:

Economic Calendar

AAII Sentiment Survey

BULL^ neut ^ BEAR

Chart

index chart
index color
SPY257.6450.500.19%41,867,194

Upgrades/Downgrades